Search results for "thrombocytosi"
showing 4 items of 24 documents
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patient…
2015
Abstract BACKGROUND: MF is a myeloproliferative neoplasm characterized by bone marrow (BM) fibrosis, splenomegaly, and debilitating constitutional symptoms. RUX is a potent JAK1/JAK2 inhibitor that has demonstrated superiority in spleen volume reduction, symptom improvement, and survival in the phase 3 COMFORT studies compared with placebo and best available therapy. PAN, a potent pan-deacetylase inhibitor, inhibits JAK signaling by disrupting the interaction between JAK2 and heat shock protein 90, a protein chaperone. PAN has demonstrated reductions in splenomegaly and improvement of BM fibrosis in phase 1/2 studies. The combination of RUX and PAN demonstrated synergistic activity in precl…
Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essent…
2010
Standardized criteria of response to treatment and a unified definition of resistance/intolerance to hydroxycarbamide (HC) in essential thrombocythaemia (ET) have been proposed by the European LeukaemiaNet (ELN). We have retrospectively evaluated such criteria in 166 ET patients treated with HC for a median of 4·5 years. Overall, 134 patients achieved a complete clinicohaematological response (CR) and 25 a partial response. Thirty-three patients met at least one of the ELN criteria defining resistance (n = 15) or intolerance (n = 21) to HC. Fifteen cases developed anaemia with thrombocytosis, which was associated with a high incidence of myelofibrosis and death from any cause. Other definit…
Is prolonged febrile syndrome associated with reactive thrombocytosis a possible association in the diagnosis of Takayasu’s arteritis? A case report
2021
Takayasu’s arteritis is a rare, systemic, inflammatory vasculitis of large blood vessels with an unknown aetiology that more frequently affects women of childbearing age with progression to stenosis, fibrosis or thrombogenesis. Clinical manifestations are associated either with inflammation of the vascular wall (including fever, myalgia, arthralgia, weight loss) or the development of aneurysms and extensive vascular lesions, which creates challenges for a differential diagnosis. This current report presents the case of a female Caucasian patient, aged 23 years, that presented herself repetitively at the hospital reporting symptoms including fever, productive cough, myalgia associated with …
Trombocitozes saistība ar ne-sīkšūnu plaušu vēža pacientu demogrāfiskajiem un klīniskajiem faktoriem
2019
Ievads. Lai gan tiek izstrādātas arvien efektīvākas ļaundabīgo audzēju agrīnas skrīninga un diagnostikas metodes, ne-sīkšūnu plaušu vēzis vēl joprojām pārsvarā tiek atklāts III vai IV stadijā, līdz ar to tas ir viens no vadošajiem audzējiem mirstības ziņā. Trombocīti piedalās vēža šūnu augšanā un tālākā izplatīšanā pa organismu. Ne-sīkšūnu plaušu vēža pacientiem bieži ir palielināts trombocītu skaits, kas ir saistīts ar sliktu prognozi. Tamdēļ, ir būtiski noskaidrot vai pastāv kādi ne-sīkšūnu plauša vēža pacienta demogrāfiskie vai klīniskie rādītāji, kam ir korelācija ar trombocitozi. Tas ļautu laicīgi paredzēt to, ka pacientam iespējams būs palielināts trombocītu skaits un izrietoši sliktā…